ARTICLE | Product Development
Moderna pushes for diverse Phase III as COVID-19 vaccine program nears enrollment target
Plus €252 million for CureVac, J&J’s challenge data and GSK- Sanofi vaccine enters clinic
September 5, 2020 2:14 AM UTC
Moderna is working to engage racial and ethnic minority communities in the Phase III trial of its mRNA COVID-19 vaccine, which is expected to complete enrollment this month.
Meanwhile, other vaccine developers provided updates on their programs this week. CureVac N.V. (NASDAQ:CVAC) is receiving a grant worth over €250 from the German government to develop its vaccine; Johnson & Johnson (NYSE:JNJ) reported a single dose of its vaccine protected hamsters; and partners Sanofi (Euronext:SAN; NASDAQ:SNY) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started clinical testing of their candidate...